Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail
-

Influenza Virus Vaccine for the 2013-2014 Season

FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met in Rockville, Maryland, on February 27, 2013, to select the influenza viruses for the composition of the influenza vaccine for the 2013-2014 U.S. influenza season. During this meeting, the advisory committee reviewed and evaluated the surveillance data related to epidemiology and antigenic characteristics of recent influenza isolates, serological responses to 2012-2013 vaccines, and the availability of candidate strains and reagents.
 

The committee recommended that the trivalent formulation influenza vaccines for the U.S. 2013-2014 influenza season contain the following:

  • an A/California/7/2009 (H1N1)-like virus;
  • an (H3N2) virus antigenically like the cell-propagated prototype virus A/Victoria/361/2011;
  • a B/Massachusetts/2/2012-like virus.
     
The committee also recommended that quadrivalent influenza vaccines contain the above three strains and the following additional B strain:
 
  • a B/Brisbane/60/2008-like virus

 

 

-
-